Chinese Medicine Interfering With Digoxin Immunoassays

Fushimi, Ryo; Tachi, Junko; Amino, Nobuyuki; Miyai, Kiyoshi

doi:10.1016/s0140-6736(89)91361-5

Cited by 19 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the Lancet , for example, a number of aspects of TCM, such as acupuncture [34-36], TCM diagnostic methods [2,37], herb-drug and herb-immunoassay interactions [38,39], as well as therapeutic and sometimes severe adverse effects of TCM drugs and adulterants [40-44] were reported. In recognition of the political, historic and cultural impacts on the development of TCM [4,5,45,46], the Lancet highlighted the development of TCM in different countries and regions, characterised by global perspectives [2,37,42,47-49].…”

Section: Reviewmentioning

confidence: 99%

The quest for modernisation of traditional Chinese medicine

Bauer

Hendry

et al. 2013

BMC Complement Altern Med

176

130

View full text Add to dashboard Cite

Traditional Chinese medicine (TCM) is an integral part of mainstream medicine in China. Due to its worldwide use, potential impact on healthcare and opportunities for new drug development, TCM is also of great international interest. Recently, a new era for modernisation of TCM was launched with the successful completion of the Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era (GP-TCM) project, the European Union’s Seventh Framework Programme (FP7) coordination action on TCM research. This 3.5-year project that involved inputs from over 200 scientists resulted in the production of 20 editorials and in-depth reviews on different aspects of TCM that were published in a special issue of Journal of Ethnopharmacology (2012; volume 140, issue 3). In this narrative review, we aim to summarise the findings of the FP7 GP-TCM project and highlight the relevance of TCM to modern medicine within a historical and international context. Advances in TCM research since the 1950s can be characterised into three phases: Phase I (1950s-1970s) was fundamental for developing TCM higher education, research and hospital networks in China; Phase II (1980s-2000s) was critical for developing legal, economic and scientific foundations and international networks for TCM; and Phase III (2011 onwards) is concentrating on consolidating the scientific basis and clinical practice of TCM through interdisciplinary, interregional and intersectoral collaborations. Taking into account the quality and safety requirements newly imposed by a globalised market, we especially highlight the scientific evidence behind TCM, update the most important milestones and pitfalls, and propose integrity, integration and innovation as key principles for further modernisation of TCM. These principles will serve as foundations for further research and development of TCM, and for its future integration into tomorrow’s medicine.

show abstract

Section: Reviewmentioning

confidence: 99%

The quest for modernisation of traditional Chinese medicine

Bauer

Hendry

et al. 2013

BMC Complement Altern Med

176

130

View full text Add to dashboard Cite

show abstract

“…4 A Chinese medicine containing kyushin ( "to save the heart") has been documented to crossreact with digoxin assays. 10 It was determined that 1 tablet of kyushin had a digoxin-like immunoreactivity equivalent to 1.9 µg (TDX analyzer; Abbott Laboratories, North Chicago, Ill) and 72 µg (Enzymun-Test; Boehringer, Mannheim, Germany) of digoxin. 10 Thus, patients with spuriously elevated digoxin levels without associated signs and symptoms of digoxin toxicity should be questioned regarding herbal therapies.…”

Section: Herbal Interactions With Cardiac Drugsmentioning

confidence: 99%

Eligibility for Outpatient Treatment With Low-Molecular-Weight Heparin in Venous Thromboembolism

Tanvetyanon¹

2000

Archives of Internal Medicine

View full text Add to dashboard Cite

“…Blood chemistry, in particular potassium, will also help as hyperkalaemia may be suggestive of the acute ingestion of cardiac glycosides. 9 Although bufadienolides may cross-react with digoxin antibodies used in digoxin immunoassays, 10 commercially available monoclonal digoxin immunoassays appear to be of little benefit in diagnosis. 11 The application of competitive radioimmunoassays with antibodies of broader specificity to cardiac glycosides is more suitable for confirming the presence of immunoreactive cardiac glycosides in serum.…”

Section: Long-term Prophylaxis and Immune Parameters In Haemophiliamentioning

confidence: 99%